br In summary the evaluation of
In summary, the evaluation of neoadjuvant therapy needs to rely on effective and reliable methods. Dynamic magnetic reso-nance imaging technology can not only provide information on the morphological changes of breast cancer lesions, but also reflect
1876-0341/© 2019 Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article in press as: Yang C, Zhao H. Application of dynamic magnetic resonance imaging information technology in adjuvant chemotherapy for breast cancer. J Infect Public Health (2019), https://doi.org/10.1016/j.jiph.2019.06.020
HE staining pathology evaluation results.
Miller-Payne Number of cases
the blood supply and tissue structure changes of the lesions. The application of dynamic magnetic resonance imaging in breast can-cer adjuvant chemotherapy is explored by collecting dynamic enhanced magnetic resonance imaging of female patients with breast cancer, and reference are provided for the diagnosis and treatment of clinical breast tumors.
Materials and methods
Image processing and analysis
The patient’s mammary gland dynamic enhanced scan image is imported into the Siemens supporting workstation and processed by Functool software. The lesions are analyzed, and the most obvi-ous areas are manually outlined and enhanced as regions of interest (ROI). The area of interest should try to avoid cystic areas, necrotic tissue, hemorrhage, calcification and vascular structure. The pro-cessing of the image and the delineation of the area of interest of the lesion are jointly handled by two senior radiologists. When the opinions are inconsistent, the director of the radiology department is consulted for consultation and discussion.
Thirty women who are diagnosed with breast cancer diagnosed at The People’s Hospital of Shanxi Province (between August 2016 and July 2018), aged 30–65 years old, with an average age of 48.05 years old, are selected. The pathological results of all patients are shown to be invasive ductal carcinoma. Informed consent is signed by all patients or their Orexin A and this study is approved by the Ethics Committee of The People’s Hospital of Shanxi Province.
The patient undergoes a needle biopsy and confirms to be uni-lateral breast cancer. The histological type is breast invasive ductal carcinoma. TAC chemotherapy is used before surgery, and then sur-gical treatment is carried out. Tumor cells do not metastasize before chemotherapy. Pathological data is complete. 2–6 cycles of neoad-juvant chemotherapy have been completed. Relevant informed consent is signed.
Patients with breast tumors are found to have other primary or secondary malignant tumors with other organ malignancies, and have a history of anti-tumor treatment. Patients with clinical stage of breast cancer are stage I and IV. Patients cannot tolerate new adjuvant chemotherapy.
Dynamic enhanced magnetic resonance imaging examination
All mammography DCE-MRI images are acquired from the SIEMENS Verio 3. TNMR scanning device has 4 channels of coils and is an open breast phased array surface coil. During the exam-ination, the patient takes the prone position, and the hands are placed flat on both sides of the body. The breasts on both sides are naturally suspended in the surface coil of the breast phase control, taking care to avoid direct contact between the breast and the coil. The scan sequence is set. Horizontal axis FLASH-3D T1WI, TIRM T2WI, FS Vibe T1WI continuous dynamic enhance scan and IVIM sequence (multi-b value EPI-DWI).
The scanning parameters are as follows: TR: 4.5 ms, TE: 2.1 ms, matrix: 256 × 232, layer thickness: 4 mm, layer spacing: 1 mm, field of view: 34 × 34 cm. Each period is 8 s, with a total of 45 periods. Before the dynamic enhancement, the mask is plainly scanned, and a contrast agent (Bismuth diamine, 0.2 mmol/kg) is intravenously injected into the patient’s arm using a high-pressure syringe at an average flow rate of 2.5 ml/s (Wuhan Xinxin Jiali Biotechnol-ogy Co., Ltd., China). Dynamic enhanced scanning can be performed after the injection is completed. IVIM sequence (multi-b value EPI-
Pathological Sumu Ziyi red staining method to evaluate the curative effect
The surgical specimens are fixed with 10% formaldehyde solu-tion (Sichuan Mianzhu Xinhua Chemical Co., Ltd., China) for 24 h. After sectioning, they are embedded in paraffin and stained with hematoxylin-eosin (HE) stain. Specimen pathology assessment is carried out by a senior doctor of pathology. Evaluation is carried out according to the Miller-Payne (MP) grading system. Level 1: tumor cell number does not decrease overall. Level 2: tumor cell reduction is less than 30%. Level 3: tumor cell number decreases by 30%–90%. Level 4: the number of tumor cells decreases by more than 90%, leaving only small clusters of scattered individual cancer cells. Level 5: no invasive cancer cells are seen in the sections, but ductal carcinoma in situ may exist.